Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia

@article{Kondo2017ClinicalIO,
  title={Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia},
  author={Takeshi Kondo and Tokiko Nagamura-Inoue and Arinobu Tojo and Fumitaka Nagamura and Naoyuki Uchida and Hirohisa Nakamae and Takahiro Fukuda and Takehiko Mori and Shingo Yano and Mineo Kurokawa and Hironori Ueno and Heiwa Kanamori and Hisako Hashimoto and Makoto Onizuka and Minoko Takanashi and Tatsuo Ichinohe and Yoshiko Atsuta and Kazuteru Ohashi},
  journal={American Journal of Hematology},
  year={2017},
  volume={92},
  pages={902–908}
}
  • Takeshi Kondo, Tokiko Nagamura-Inoue, +15 authors Kazuteru Ohashi
  • Published in
    American journal of…
    2017
  • Medicine
  • American Journal of Hematology
  • Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with chronic myelogenous leukemia in the chronic phase (CML-CP), and outcomes of TKI treatment for patients with CML-CP have been excellent. Since multiple TKIs are currently available, second-line or third-line TKI therapy is considered for patients who are intolerant of or resistant to the previous TKI treatment. Therefore, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered only for patients with… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 35 REFERENCES

    Chronic myeloid leukaemia

    VIEW 1 EXCERPT

    Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.